Antibody-Drug Conjugates (ADCs)

The Magic Bullet Concept

Paul Ehrlich, the Nobel Prize-winning immunologist, proposed in the early 1900s that it might be possible to create a "magic bullet" — a compound that selectively targets and kills pathogens or cancer cells without harming healthy tissue. Antibody-drug conjugates (ADCs) are the closest realization of that vision in oncology.

Traditional chemotherapy distributes throughout the body, killing rapidly dividing cells — including healthy ones in hair follicles, bone marrow, and the gastrointestinal tract. ADCs aim to concentrate cytotoxic (cell-killing) drugs at the tumor while sparing normal tissue, improving the therapeutic window.

Anatomy of an ADC

Every ADC has three components:

1. Antibody: A monoclonal antibody engineered to bind a protein (antigen) that is highly expressed on the surface of cancer cells but present at low or absent levels on normal cells. The antibody component provides targeting specificity.

2. Payload (cytotoxin): A small-molecule drug, typically far too toxic to administer systemically at effective doses. Common payloads include auristatins (microtubule disruptors), maytansinoids (also microtubule disruptors), and calicheamicins (DNA strand breakers). Payloads are often 100–1,000 times more potent than conventional chemotherapy agents.

3. Linker: A chemical bridge connecting the antibody to the payload. The linker determines when and where the payload is released — ideally only inside cancer cells.

How ADCs Kill Cancer Cells

The sequence of events after an ADC is infused:

1. The antibody circulates in the bloodstream until it encounters cells expressing its target antigen.
2. The ADC binds the antigen on the cancer cell surface.
3. The cell internalizes the ADC through endocytosis (the cell membrane engulfs it).
4. Inside the cell's lysosomes (acidic compartments that break down material), the linker is cleaved and the payload is released.
5. The free payload exerts its cytotoxic effect — disrupting microtubules, damaging DNA, or triggering apoptosis.

Some ADC payloads also exhibit a "bystander effect": after release, the highly membrane-permeable toxin diffuses into neighboring cancer cells, even those that do not express the target antigen. This can be beneficial when tumors are heterogeneous (not all cells express the same level of the antigen).

The Linker Problem

Early ADC failures were often due to linker instability — the payload was released prematurely in the bloodstream before reaching the tumor. Modern cleavable linkers are designed to be stable in plasma pH but rapidly cleaved in the acidic lysosomal environment of cancer cells. Non-cleavable linkers rely on the entire antibody being degraded inside the cell to release the payload as an amino acid-payload conjugate.

The drug-to-antibody ratio (DAR) — the number of payload molecules per antibody — also matters. Too few payloads reduce potencyPotency

The amount of drug needed to produce a given effect. A more potent drug achieves the same effect at a lower dose. Potency is different from efficacy — a drug can be highly potent but have limited maxi

; too many can cause aggregation and off-target toxicity. ADCs typically have a DAR of 2–8.

Approved ADCs

The ADC field has grown rapidly. Approved examples include:

• Kadcyla (ado-trastuzumab emtansine): Targets HER2-positive breast cancer. Combines trastuzumab (Herceptin) with a maytansinoid payload.
• Enhertu (trastuzumab deruxtecan): Next-generation HER2-targeting ADC with a camptothecin payload; approved for breast, lung, and gastric cancers.
• Padcev (enfortumab vedotin): Targets Nectin-4, approved for urothelial (bladder) cancer.
• Trodelvy (sacituzumab govitecan): Targets TROP-2, approved for triple-negative breast cancer and urothelial cancer.
• Besylomab/Mylotarg (gemtuzumab ozogamicin): Targets CD33, used for acute myeloid leukemia. It was voluntarily withdrawn in 2010 over safety concerns and re-approved in 2017 at a lower dose.

As of 2025, over a dozen ADCs have regulatory approval, and more than 100 are in clinical development.

Side Effects and Toxicity

ADCs are not without side effects. Despite their targeting mechanism, some payload release occurs in normal tissues. Common toxicities include:

• Hematologic toxicity: Low blood counts (neutropenia, thrombocytopenia), particularly with payload types that affect bone marrow.
• Peripheral neuropathy: Seen especially with auristatin-based ADCs (Padcev, Adcetris).
• Interstitial lung disease (ILD): A serious and potentially fatal side effect notably associated with Enhertu, requiring careful monitoring.
• Ocular toxicity: Corneal changes observed with some TROP-2-targeting ADCs.

ADCs vs. Traditional Biologic Drugs

A standard biologic drugBiologic Drug

A medication derived from living organisms or their components, including proteins, antibodies, vaccines, and gene therapies. Biologics are larger and more complex than traditional small-molecule drug

— a monoclonal antibody alone — works by blocking a signaling pathway, recruiting immune cells, or marking cancer cells for destruction. ADCs go further: they use the antibody's targeting ability to deliver an active killer directly to the cancer cell, combining the precision of a biologic with the potency of chemotherapy. This makes ADCs effective even against some cancer types that have become resistant to antibody-only therapies.

Key Takeaways

• ADCs combine a cancer-targeting antibody with a highly potent cytotoxic payload, connected by a chemical linker.
• They kill cancer cells from within after antibody-mediated internalization and lysosomal linker cleavage.
• Linker stability and drug-to-antibody ratio are key engineering parameters that determine safety and efficacyEfficacy

  The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than one with lower efficacy, even if the latter is

  .
• Over a dozen ADCs are approved; the field is one of the fastest-growing in oncology.
• Side effects still occur — particularly neuropathy, blood count changes, and lung inflammation — and require active monitoring.